
---
title: '呼吸道合胞病毒疫苗和单抗最新研究进展（2）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=946353'
author: 科学网
comments: false
date: Sat, 13 Aug 2022 06:32:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=946353'
---

<div>   
<p><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px">呼吸道合胞病毒预防</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px">制剂曙光在前:</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px"><a name="OLE_LINK1" href="http://blog.sciencenet.cn/undefined"></a></span></strong><strong>　</strong><br></p><p><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px">疫苗和单</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px">克隆</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px">抗</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 35px"><span style="font-family:Shaker2Lancet-Bold">体</span><span style="font-family:Shaker2Lancet-Bold">百舸争流</span></span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:59px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 29px">前言：</span></strong></p><p style="margin: 16px 0px; text-indent: 48px; padding: 0px; background: rgb(255, 255, 255); line-height: 2em;"><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">新冠病毒大流行的将近３年，也是世界疫苗行业突飞猛进、疫苗研发技术日新月异、硕果累累的３年。疫苗制备的多种技术途径都得到深度开发，若干种新兴的技术途径如</span><span style="font-family:Microsoft YaHei UI">mRNA疫苗获得了空前的成功，在世界各地大行其道，在多种传染病以及癌症和其他慢性病的防治领域都在不断开花结果。</span></span></strong></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; background: rgb(255, 255, 255); line-height: 2em;"><strong>　　</strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">呼吸道合胞病毒（</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px">Respiratory syncytial virus</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px"><span style="font-family:Shaker2Lancet-Bold">，</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px"><span style="font-family:Shaker2Lancet-Bold">）</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">是一种历史悠久、危害极大的传染病，其疫苗的研发已经有四十年的历史，</span><span style="font-family:Microsoft YaHei UI"> 但最初开发的疫苗反而会引发</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">疫苗相关性呼吸道疾病（</span><span style="font-family:Microsoft YaHei UI">VAERD，Vaccine-associated enhanced respiratory diseases</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px">）</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">，即未接触过</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的儿童在接种了疫苗后，如果再接触到该病毒反而会发生更严重的</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疾病。诸如此类的问题导致针对</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗一直未能上市。乘新冠病毒疫苗大跃进的东风，已赚得盆满钵满的疫苗巨头如</span></strong><a href="https://zh.wikipedia.org/wiki/%E8%BE%89%E7%91%9E" title="辉瑞" target="_blank"><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #6666CC;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">辉瑞</span></span></span></a><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">（</span><span style="font-family:Microsoft YaHei UI">Pfizer)</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">、</span></strong><a href="https://zh.wikipedia.org/wiki/%E8%8E%AB%E5%BE%B7%E7%BA%B3" title="莫德纳" target="_blank"><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #6666CC;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">莫德纳</span></span></span></a><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">（</span><span style="font-family:Microsoft YaHei UI">Moderna</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">）和</span></strong><a href="https://zh.wikipedia.org/wiki/%E8%91%9B%E5%85%B0%E7%B4%A0%E5%8F%B2%E5%85%8B" title="葛兰素史克" target="_blank"><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #6666CC;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">葛兰素史克</span></span></span></a><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">(GSK)</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">等目前都在</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">的疫苗开发上快马加鞭，有望在较短时间内取得重大突破。</span></strong></p><p style="margin: 16px 0px; text-indent: 48px; padding: 0px; background: rgb(255, 255, 255); line-height: 2em;"><strong><span style="text-decoration:underline;"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:Microsoft YaHei UI">RSV</span></span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">疫苗和单克隆抗体研究领域来自世界各地的顶级研究人员（约５０人）近期联名在国际著名专业杂志《</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #FF0000;letter-spacing: 0;font-size: 24px">Lancet</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px"> Infect Dis》上发表综述论文，介绍相关最新研究进展（见</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 0;font-size: 24px">参考文献</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px">），本博客将分数次介绍此综述的主要内容。</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 29px">　　目录：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px">摘要</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">一</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px">前言</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">二</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px">方法</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">三</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">教训（</span>Lessons learned）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">四</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">活的减毒疫苗（</span>liveattenuated vaccines，LAVs ）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">五</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">嵌合疫苗（</span>Chimeric ）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">六</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">亚单位疫苗（</span>Subunit）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">七</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">基于颗粒的疫苗（</span>Particle-based ）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">八</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">核酸疫苗（</span>Nucleic acid）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">九</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">重组载体疫苗（</span>Recombinant vectors）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">十</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">单克隆抗体（</span>MAbs）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">十一</span>.　</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 21px"><span style="font-family:Shaker2Lancet-Bold">讨论</span> </span></strong></p><p><span style="font-family:Shaker2Lancet-Bold;color:#231F20;font-weight:bold;font-size:24px">一.　</span><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;font-size: 24px">前言</span></strong><span style="font-family: Calibri; font-size: 14px;"> </span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在过去的十年中，</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">呼吸道合胞病毒</span>(<a name="OLE_LINK3" href="http://blog.sciencenet.cn/undefined"></a></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)的巨大负担在全球得到了越来越多的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">承认</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">RSV</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:ScalaLancetPro">是新生儿期之后婴儿死亡的第二大原因</span></span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">,99%的儿童死亡发生在</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">低收入和中等收入国家</span><a name="OLE_LINK2" href="http://blog.sciencenet.cn/undefined"></a>(LMICs</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">，</span></span></span></strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"> low-income and middle-income countries</span></span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">)</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">然而</span>,儿童的</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">负担可能被低估了，关于</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疾病负担的知识的重大差距</span><span style=";font-family:SimSun;line-height:200%;color:#231F20;font-size:19px">问题</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">直到最近才得到解决。</span></p><p style="margin-top:0;margin-right:4px;margin-bottom:0;margin-left:0;text-indent:43px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在贫困为主要风险因素的低收入和中等收入国家</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">(LMICs</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">）</span></span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">中，超过</span>50%的儿童</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">死亡发生在医院外</span>(而不是在医院</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">内</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)(</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#FF0000;font-size:19px"><span style="font-family:ScalaLancetPro">图</span>1</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)。</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">高收入国家</span>(high-income countries</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">，</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">HICs</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)中</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疾病风险最高的婴儿包括早产儿和患有潜在先天性心脏病或慢性肺部疾病</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">、</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">唐氏综合症和神经肌肉</span><span style="font-family: 'Microsoft YaHei';line-height: 200%;color: #2A2B2E;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">失调症</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的婴儿</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">孕妇接种疫苗不足以保护极度早产的婴儿，因为经胎盘的抗体转移只在妊娠</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的终</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">末期</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">才能</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">达到成熟水平</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">直到最近，在</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">年龄大于</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">60岁</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">老人中</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">引起的发病率和死亡率负担也一直被低估。目前的模拟研究估计，</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">RSV</span></span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:ScalaLancetPro">在</span>65岁以上成年人中的负担类似于季节性流感的负担。</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">初步经济评估</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">彰显</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">了一种针对老年人的疫苗的潜在价值，特别是在高收入国家。成本效益的主要经济驱动因素包括</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">发病率、死亡风险以及保护水平和持续时间</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">的自然免疫是不完全的，整个生命过程中都会发生</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">的重新感染</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗开发中的一个问题是，在接种</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗后，自然感染可能导致更严重的呼吸道疾病</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">，在</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">20世纪60年代</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在以前</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">未</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">曾</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">感染</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">过</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的婴儿</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">中</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">使用福尔马林灭活</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗后就</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">观察到</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">这种情况。</span><span style=";font-family:SimSun;line-height:200%;font-size:19px">引发的更严重</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">呼吸道疾病与疫苗受体中弱中和抗体的诱导有关，</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">更严重</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">的呼吸道疾病动物模型显示</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">，存在</span><span style=";font-family:Calibri;line-height:200%;font-size:19px">T<span style="font-family:SimSun">辅助细胞</span><span style="font-family:Calibri">2</span><span style="font-family:SimSun">型</span><span style="font-family:Calibri">(Th2)</span><span style="font-family:SimSun">偏向性</span><span style="font-family:Calibri">T</span><span style="font-family:SimSun">细胞反应</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">。</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">因此，针对</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">从未感染过</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:SimSun;line-height:200%;font-size:19px">的疫苗接种者</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">的</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">理想的</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">疫苗</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">应当能</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">诱导</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">高</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">效的中和抗体，</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">同时</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">不存在</span>Th2<span style="font-family:SimSun">偏</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">向性</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">。</span></span></p><p style="margin-left:0;text-indent:43px;text-autospace:ideograph-numeric;line-height:200%"><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">虽然对</span></span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">感染保护的确切关联仍然不明确，细胞介导的免疫</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">、</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">粘膜</span>IgA<span style="font-family:SimSun">和中和抗体</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">都</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">已经</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">确认</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">与</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px">针</span><span style=";font-family:Calibri;line-height:200%;font-size:19px"><span style="font-family:SimSun">对</span>RSV<span style="font-family:SimSun">感染的保护有关。</span></span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">融合</span>(F)蛋白</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">融合前</span>(pre-F)</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">构象的稳定导致了对</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">能诱导</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">高</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">效</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">中和抗体的病毒表位的确定。识别</span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">融合前</span>(pre-F)</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">构象</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的抗体在人</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">免疫</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">血清</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">中提供了大部分的中和活性，支持基于稳定的</span>pre-F抗原的候选疫苗和</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">单克隆抗体</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"> (mAbs)</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">的开发</span>(</span><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:ScalaLancetPro">图</span>2</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">预防</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:ScalaLancetPro">有三种不同的目标人群</span>:儿科</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">人群</span></strong><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #FF0000;font-size: 19px">、孕产妇和老年人</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#FF0000;font-size:19px">(图3</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。对</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">儿科人群的主要策略包括对</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">不足</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">6个月</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">小婴儿使用单抗进行被动免疫预防，对</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">大于</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">6个月</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">大婴儿使用</span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">减毒</span></span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">活疫苗</span>(LAVs)</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">进行主动免疫。接种过疫苗的孕妇中被动传递的抗体也可能保护婴儿。用于产妇接种的稳定</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">pre-F</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">亚</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">单位</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">正</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">处于后期开发阶段。最后，对老年人使用</span>pre-F抗原的三种疫苗接种方法(核酸疫苗、亚</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">单位</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">疫苗和</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">基于</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">载体</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">疫苗</span>)处于后期</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">临床</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">试验阶段。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">2018年，我们</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">曾</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">对</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">疫苗进行了全面综述，总结了后期疫苗失败的经验教训，确定了</span>19种候选疫苗和临床试验中的单克隆抗体</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">该综述通过认可</span>pre-F作为</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">预防干预的新靶点，可能为疫苗开发人员提供未来疫苗开发的指导。</span>pre-F抗原现在是6种候选疫苗和2种</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">处于</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">3期</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">临床</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">试验</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">阶段</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">单克隆抗体的基础</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">此外，我们支持将</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">受</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">控制</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">人类感染模型作为一种独特的工具，以快速证明保护概念和广泛的免疫学特性。该方法已被用于</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">当前的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">六</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">种</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">候选疫苗</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">临床开发</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">：</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">MV-012-968, </span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">Pre-F，MVA-BN-</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">, palivizumab</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">biosimilar, clesrovimab, and Ad26.</span><strong><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #00B050;font-size: 19px">RSV</span></span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">.Pre-F</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">。</span></p><p style="margin-left:0;text-indent:43px;text-autospace:ideograph-numeric;line-height:200%"><span style=";font-family:SimSun;line-height:200%;font-size:19px"><span style="font-family:SimSun">本次更新后的综述显示，</span><span style="font-family:Calibri">2018</span><span style="font-family:SimSun">年的</span><span style="font-family:Calibri">19</span><span style="font-family:SimSun">种候选疫苗中有</span><span style="font-family:Calibri">11</span><span style="font-family:SimSun">种</span><span style="font-family:Calibri">(58%)(2015</span><span style="font-family:SimSun">年综述中是</span><span style="font-family:Calibri">10</span><span style="font-family:SimSun">种候选疫苗中有</span><span style="font-family:Calibri">3</span><span style="font-family:SimSun">种</span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"> [30%] </span><span style=";font-family:SimSun;line-height:200%;font-size:19px"><span style="font-family:Calibri">)</span><span style="font-family:SimSun">在继续开发，同时该领域也在扩大，额外另有</span><span style="font-family:Calibri">19</span><span style="font-family:SimSun">种候选疫苗已进入临床试验</span><span style="font-family:Calibri">(</span></span><span style=";font-family:SimSun;line-height:200%;color:#FF0000;font-size:19px"><span style="font-family:SimSun">图</span><span style="font-family:Calibri">2</span><span style="font-family:SimSun">，图</span><span style="font-family:Calibri">4</span></span><span style=";font-family:SimSun;line-height:200%;font-size:19px"><span style="font-family:Calibri">)</span><span style="font-family:SimSun">。最后，在</span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">SAR-CoV-2</span></span><span style="text-decoration:underline;"><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px"><span style="font-family:ScalaLancetPro">（新冠病毒</span></span></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">）的</span><span style=";font-family:SimSun;line-height:200%;font-size:19px"><span style="font-family:Calibri">mRNA</span><span style="font-family:SimSun">疫苗开发成功后，以</span><span style="font-family:Calibri">mRNA</span><span style="font-family:SimSun">形式接种的疫苗是一种新的预防方法，已迅速进入后期临床试验。</span></span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">（未完待续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 24px">参考文献：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">Natalie I Mazur,</span></em><em>　</em><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">et al., </span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">Respiratory syncytial virus prevention within reach:</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"> the vaccine and monoclonal antibody landscape, </span></strong><em><span style="font-family: Shaker2Lancet-Bold;color: #FF0000;letter-spacing: 0;font-size: 20px">Lancet Infect Dis</span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"><span style="font-family:Shaker2Lancet-Bold">，</span> Published online August 8, 2022， </span></strong><span style="font-family: Tahoma;color: #505050;letter-spacing: 0;font-size: 20px">DOI: </span><a href="https://doi.org/10.1016/S1473-3099(22)00291-2" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px">https://doi.org/10.1016/S1473-3099(22)00291-2</span></a><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 20px">，</span></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 28px; background: rgb(255, 255, 255);"><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Shaker2Lancet-Bold;color: #6666CC;letter-spacing: 0;font-size: 20px">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext</span></span></a><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">.</span></strong></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 28px; background: rgb(255, 255, 255);"><span style="font-size: 24px;"><strong><span style="font-family: Shaker2Lancet-Bold; color: #231F20; letter-spacing: 0px;">相关博文：</span></strong></span></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 28px; background: rgb(255, 255, 255);"><span style="font-size: 20px;"><strong><span style="font-family: Shaker2Lancet-Bold; color: #231F20; letter-spacing: 0px;"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank" style="overflow-wrap: break-word; text-decoration-line: none; font-family: Tahoma, Helvetica, SimSun, sans-serif, Hei; font-size: 12px; font-weight: 700; white-space: normal; background-color: rgb(255, 255, 255); color: rgb(102, 102, 204) !important;"></a></span></strong></span></p><p><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=946353" title alt="image.png" referrerpolicy="no-referrer"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（１）</span></span></span></strong></a><strong style="font-size: 20px; background-color: rgb(255, 255, 255);"><span style="font-family: Shaker2Lancet-Bold; color: #231F20; letter-spacing: 0px;"><span class="xg2 xw0" style="overflow-wrap: break-word; color: #666666; font-family: Tahoma, Helvetica, SimSun, sans-serif, Hei;"> 2022-08-12</span></span></strong></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1350986.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1350986.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1350903.html" target="_black">呼吸道合胞病毒疫苗和单抗最新研究进展（１）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            